Table 1. Demographic and clinical characteristics of patients with ACPA-negative undifferentiated arthritis.
| N=402 | |
|---|---|
| Age | 52.9 (14.9) |
| Female gender | 299 (74.4) |
| Psoriasis (family history) | 31 (7.7) |
| Symptoms duration, weeks | 22.4 (12–36.1) |
| Symptoms duration (weeks) | |
| <6 | 25 (6.2) |
| <12 | 91 (22.6) |
| Morning stiffness (min) | |
| <30 | 91 (22.6) |
| 30–60 | 180 (44.8) |
| >60 | 131 (32.6) |
| SJC28 | 2.5 (1.9) |
| SJC44 | 2.9 (2.4) |
| Monoarthritis (1) | 122 (30.3) |
| Oligoarthritis (2–5) | 254 (63.2) |
| Polyarthritis (6–28) | 26 (6.5) |
| Symmetric arthritis | 162 (40.3) |
| TJC28 | 3.7 (4.9) |
| TJC46 | 5.7 (7.6) |
| DAS28 | 3.64 (1) |
| VAS pain | 54.2 (25.6) |
| PGA | 51.9 (25.2) |
| HAQ | 0.63 (0.53) |
| ESR | 15.1 (15.1) |
| CRP | 0.7 (1.2) |
| RF | 18 (4.5) |
| ANA | 186 (46.3) |
| SHS erosion score ≥1 | 30 (7.5) |
ACPA, anticitrullinated protein autoantibodies; ANA, antinuclear antibody; CRP, C reactive protein; DAS28, 28-joints Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; PGA, Patient Global Assessment; RF, rheumatoid factor; SHS, Sharp van der Heijde Score; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.